<p>Guardant Health, Inc.（納斯達克代碼：GH - 獲取免費報告）董事 Musa Tariq 於 3 月 18 日（星期三）出售了 348 股該公司的股票。股票的平均售價為 88.09 美元，總交易額為 30,655.32 美元。出售後，該董事持有 8,394 股公司的股票，估值約為 739,427.46 美元。此次交易使其持股減少了 3.98%。該交易已在與 SEC 的法律文件中披露，相關信息可通過此鏈接獲取。</p>
<p>獲取 <strong>Guardant Health</strong> 的提醒：</p>
<h2>Guardant Health 股價上漲 2.1%</h2>
<ul>
<li>4 只醫療保健股票大幅上漲——還有更多機會</li>
</ul>
<p>週四，GH 股價上漲 1.81 美元，達到 89.08 美元。該公司的交易量為 1,228,613 股，而其平均交易量為 2,012,589 股。該公司的 50 日移動平均價格為 102.70 美元，200 日移動平均價格為 90.31 美元。Guardant Health, Inc.的 1 年最低價為 36.36 美元，1 年最高價為 120.74 美元。該公司的市值為 116.8 億美元，市盈率為-26.91，貝塔值為 1.67。</p>
<p>Guardant Health（納斯達克代碼：GH - 獲取免費報告）最近於 2 月 19 日（星期四）發佈了季度財報。該公司報告本季度每股收益（EPS）為-0.50 美元，低於市場共識預期的-0.43 美元，差額為 0.07 美元。該公司本季度的收入為 2.8127 億美元，而分析師預期為 2.6974 億美元。在去年同期，該公司每股收益為-0.62 美元。該公司本季度的收入同比增長 39.4%。分析師平均預測，Guardant Health, Inc.在當前年度的每股收益將為-2.9。</p>
<h2>Guardant Health 的機構交易</h2>
<ul>
<li>解讀顛覆：深入瞭解 Cathie Wood 的最新投資</li>
</ul>
<p>一些對沖基金最近增持或減持了 GH 的股份。V Square Quantitative Management LLC 在第四季度新購入了 Guardant Health 的股份，價值約 27,000 美元。Chesapeake Asset Management LLC 在第四季度新購入了 Guardant Health 的股份，價值約 28,000 美元。Thurston Springer Miller Herd &amp; Titak Inc.在第四季度新購入了 Guardant Health 的股份，價值約 31,000 美元。Elyxium Wealth LLC 在第四季度新購入了 Guardant Health 的股份，價值約 35,000 美元。最後，Parallel Advisors LLC 在第四季度將其在 Guardant Health 的持股增加了 164.7%。Parallel Advisors LLC 目前持有該公司 352 股股票，價值 36,000 美元，此前在上個季度又購買了 219 股。92.60% 的股票由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師的看法</h2>
<p>幾位研究分析師最近對 GH 股票發佈了報告。Weiss Ratings 在 1 月 22 日的報告中重申了對 Guardant Health 股票的 “賣出（d-）” 評級。Canaccord Genuity Group 在 2 月 20 日的研究報告中將 Guardant Health 的目標價從 125.00 美元上調至 135.00 美元，並給予該公司 “買入” 評級。瑞銀集團在 1 月 30 日的報告中重申了 “買入” 評級，並對 Guardant Health 的目標價為 175.00 美元。Leerink Partners 在 2 月 20 日的研究報告中將 Guardant Health 的目標價從 170.00 美元上調至 180.00 美元，並給予該公司 “跑贏大盤” 評級。最後，Stifel Nicolaus 在 2 月 20 日的報告中將 Guardant Health 的目標價從 120.00 美元上調至 130.00 美元，並給予該公司 “買入” 評級。21 位分析師對該股票給予了買入評級，1 位給予了持有評級，1 位給予了賣出評級。根據 MarketBeat 的數據，Guardant Health 目前的平均評級為 “適度買入”，平均目標價為 122.57 美元。</p>
<ul>
<li>3 只快速增長的股票分析師認為價格將翻倍</li>
</ul>
<p><strong>閲讀我們對 Guardant Health 的最新股票分析</strong></p>
<h2>關於 Guardant Health</h2>
<p>（獲取免費報告）</p>
<p>Guardant Health, Inc.是一家專注於血液癌症診斷的精準腫瘤學公司。公司成立於 2012 年，總部位於加利福尼亞州紅木城，開發非侵入性測試，利用循環腫瘤 DNA（ctDNA）對實體腫瘤患者的基因組變化進行分析。Guardant Health 的使命是通過向全球臨牀醫生、製藥合作伙伴和研究人員提供可操作的數據，推動癌症護理的進步。</p>
<p>該公司的旗艦產品 Guardant360 是一種下一代測序（NGS）檢測，旨在檢測 70 多種與癌症相關的基因中的突變、拷貝數變化和特定融合。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們認為比 Guardant Health 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
<p>在考慮 Guardant Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Guardant Health 並不在名單上。</p>
<p>雖然 Guardant Health 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>Guardant Health 的董事 Musa Tariq 出售了 348 股，價格為每股 88.09 美元，總計 30,655.32 美元，代表其持股減少了 3.98%。出售後，他持有 8,394 股，估值約為 739,427.46 美元。該交易已向美國證券交易委員會（SEC）披露。Guardant Health 的股票最近交易價格為 89.08 美元，市值為 116.8 億美元。分析師的評級意見不一，平均目標價共識為 122.57 美元，顯示出 “適度買入” 的評級。該公司專注於基於血液的癌症診斷，並在最近的財報中報告了同比 39.4% 的收入增長</p>

<p>Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 348 shares of the firm's stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $88.09, for a total transaction of $30,655.32. Following the sale, the director owned 8,394 shares of the company's stock, valued at approximately $739,427.46. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.</p>
<div class="lb-trans"><p>Guardant Health, Inc.（納斯達克代碼：GH - 獲取免費報告）董事 Musa Tariq 於 3 月 18 日（星期三）出售了 348 股該公司的股票。股票的平均售價為 88.09 美元，總交易額為 30,655.32 美元。出售後，該董事持有 8,394 股公司的股票，估值約為 739,427.46 美元。此次交易使其持股減少了 3.98%。該交易已在與 SEC 的法律文件中披露，相關信息可通過此鏈接獲取。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Guardant Health</strong> 的提醒：</p>
</div><h2>Guardant Health Trading Up 2.1%</h2>
<div class="lb-trans"><h2>Guardant Health 股價上漲 2.1%</h2>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只醫療保健股票大幅上漲——還有更多機會</li>
</ul>
</div><p>GH traded up $1.81 on Thursday, hitting $89.08. The company had a trading volume of 1,228,613 shares, compared to its average volume of 2,012,589. The company's fifty day moving average price is $102.70 and its 200 day moving average price is $90.31. Guardant Health, Inc. has a 1 year low of $36.36 and a 1 year high of $120.74. The firm has a market cap of $11.68 billion, a P/E ratio of -26.91 and a beta of 1.67.</p>
<div class="lb-trans"><p>週四，GH 股價上漲 1.81 美元，達到 89.08 美元。該公司的交易量為 1,228,613 股，而其平均交易量為 2,012,589 股。該公司的 50 日移動平均價格為 102.70 美元，200 日移動平均價格為 90.31 美元。Guardant Health, Inc.的 1 年最低價為 36.36 美元，1 年最高價為 120.74 美元。該公司的市值為 116.8 億美元，市盈率為-26.91，貝塔值為 1.67。</p>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same period in the prior year, the company posted ($0.62) EPS. The firm's revenue for the quarter was up 39.4% on a year-over-year basis. On average, analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.</p>
<div class="lb-trans"><p>Guardant Health（納斯達克代碼：GH - 獲取免費報告）最近於 2 月 19 日（星期四）發佈了季度財報。該公司報告本季度每股收益（EPS）為-0.50 美元，低於市場共識預期的-0.43 美元，差額為 0.07 美元。該公司本季度的收入為 2.8127 億美元，而分析師預期為 2.6974 億美元。在去年同期，該公司每股收益為-0.62 美元。該公司本季度的收入同比增長 39.4%。分析師平均預測，Guardant Health, Inc.在當前年度的每股收益將為-2.9。</p>
</div><h2>Institutional Trading of Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 的機構交易</h2>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解讀顛覆：深入瞭解 Cathie Wood 的最新投資</li>
</ul>
</div><p>A number of hedge funds have recently added to or reduced their stakes in GH. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health in the fourth quarter worth approximately $27,000. Chesapeake Asset Management LLC acquired a new position in Guardant Health during the fourth quarter worth approximately $28,000. Thurston Springer Miller Herd &amp; Titak Inc. purchased a new position in Guardant Health during the fourth quarter worth approximately $31,000. Elyxium Wealth LLC purchased a new position in Guardant Health during the fourth quarter worth approximately $35,000. Finally, Parallel Advisors LLC boosted its holdings in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company's stock valued at $36,000 after purchasing an additional 219 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些對沖基金最近增持或減持了 GH 的股份。V Square Quantitative Management LLC 在第四季度新購入了 Guardant Health 的股份，價值約 27,000 美元。Chesapeake Asset Management LLC 在第四季度新購入了 Guardant Health 的股份，價值約 28,000 美元。Thurston Springer Miller Herd &amp; Titak Inc.在第四季度新購入了 Guardant Health 的股份，價值約 31,000 美元。Elyxium Wealth LLC 在第四季度新購入了 Guardant Health 的股份，價值約 35,000 美元。最後，Parallel Advisors LLC 在第四季度將其在 Guardant Health 的持股增加了 164.7%。Parallel Advisors LLC 目前持有該公司 352 股股票，價值 36,000 美元，此前在上個季度又購買了 219 股。92.60% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師的看法</h2>
</div><p>Several research analysts have recently issued reports on GH shares. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Guardant Health in a report on Thursday, January 22nd. Canaccord Genuity Group upped their price objective on shares of Guardant Health from $125.00 to $135.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, February 20th. UBS Group reissued a &#34;buy&#34; rating and issued a $175.00 target price on shares of Guardant Health in a report on Friday, January 30th. Leerink Partners lifted their target price on Guardant Health from $170.00 to $180.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, February 20th. Finally, Stifel Nicolaus raised their target price on Guardant Health from $120.00 to $130.00 and gave the company a &#34;buy&#34; rating in a report on Friday, February 20th. Twenty-one analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Guardant Health currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $122.57.</p>
<div class="lb-trans"><p>幾位研究分析師最近對 GH 股票發佈了報告。Weiss Ratings 在 1 月 22 日的報告中重申了對 Guardant Health 股票的 “賣出（d-）” 評級。Canaccord Genuity Group 在 2 月 20 日的研究報告中將 Guardant Health 的目標價從 125.00 美元上調至 135.00 美元，並給予該公司 “買入” 評級。瑞銀集團在 1 月 30 日的報告中重申了 “買入” 評級，並對 Guardant Health 的目標價為 175.00 美元。Leerink Partners 在 2 月 20 日的研究報告中將 Guardant Health 的目標價從 170.00 美元上調至 180.00 美元，並給予該公司 “跑贏大盤” 評級。最後，Stifel Nicolaus 在 2 月 20 日的報告中將 Guardant Health 的目標價從 120.00 美元上調至 130.00 美元，並給予該公司 “買入” 評級。21 位分析師對該股票給予了買入評級，1 位給予了持有評級，1 位給予了賣出評級。根據 MarketBeat 的數據，Guardant Health 目前的平均評級為 “適度買入”，平均目標價為 122.57 美元。</p>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增長的股票分析師認為價格將翻倍</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on Guardant Health</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Guardant Health 的最新股票分析</strong></p>
</div><h2>About Guardant Health</h2>
<div class="lb-trans"><h2>關於 Guardant Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.</p>
<div class="lb-trans"><p>Guardant Health, Inc.是一家專注於血液癌症診斷的精準腫瘤學公司。公司成立於 2012 年，總部位於加利福尼亞州紅木城，開發非侵入性測試，利用循環腫瘤 DNA（ctDNA）對實體腫瘤患者的基因組變化進行分析。Guardant Health 的使命是通過向全球臨牀醫生、製藥合作伙伴和研究人員提供可操作的數據，推動癌症護理的進步。</p>
</div><p>The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.</p>
<div class="lb-trans"><p>該公司的旗艦產品 Guardant360 是一種下一代測序（NGS）檢測，旨在檢測 70 多種與癌症相關的基因中的突變、拷貝數變化和特定融合。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Guardant Health 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Guardant Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Guardant Health 並不在名單上。</p>
</div><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Guardant Health 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock

Market Beat

Guardant Health

標普生物技術 3 倍做多 - Direxion

標普生物技術 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

基因免疫&健康關懷 ETF - iShares

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

內幕交易：Guardant Health（納斯達克代碼：GH）的一位董事出售了 348 股股票